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Unaltered myocilin expression in the blood of primary open angle
glaucoma patients
Khaled K. Abu-Amero,1,2 Taif Anwar Azad,1 George L. Spaeth,3 Jonathan Myers,3 L. Jay Katz,3
Marlene Moster,3 Thomas M. Bosley1
1Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2Department of Ophthalmology,
College of Medicine, University of Florida, Jacksonville, FL; 3William and Anna Goldberg Glaucoma Service, Wills Eye Hospital,
Thomas Jefferson University, Philadelphia, PA
Purpose: To investigate the expression of the myocilin gene (MYOC) in the blood of primary open angle glaucoma
(POAG) patients to determine if altered systemic expression is playing a role.
Methods: Patients (n=47) were eligible for inclusion if they met standard clinical criteria for POAG. Control subjects
(n=27) were recruited who were free from glaucoma by examination. RNA was extracted from leukocytes of patients and
controls and converted to cDNA by reverse transcriptase enzyme, and quantitative PCR was used to assess expression
levels of MYOC and the house keeping gene β-globulin (HBB). The ratio of MYOC expression to HBB expression for
POAG patients was compared to that of controls and to clinical characteristics of POAG patients.
Results: Mean gene expression values were statistically similar in POAG patients and controls for both MYOC (p≤0.55)
and HBB (p≤0.48). MYOC/HBB ratios were also statistically indistinguishable between POAG patients and controls
(p≤0.90). MYOC/HBB ratios were not significantly associated with age, sex, or ethnicity of patients within the POAG
group. Similarly, MYOC/HBB ratios were not significantly associated with clinical parameters related to POAG severity,
including maximum intraocular pressure, vertical cup-to-disk ratio, static perimetry mean deviation, or static perimetry
pattern standard deviation.
Conclusions: MYOC expression is not altered in the blood of POAG patients, unlike MYOC expression in trabecular
meshwork (TM) cultures. These results suggests that MYOC expression is not altered systemically but rather that
MYOC expression may contribute to POAG pathogenesis in specific tissues such as TM.
Glaucoma is one of the leading causes of blindness
worldwide [1,2], characterized by chronic degeneration of
axons in the optic nerve head. Primary open angle glaucoma
(POAG) is the most prevalent type of glaucoma in western
countries and has risk factors that include elevated intraocular
pressure (IOP) and age [3]. Elevated IOP is associated with
increased aqueous humor outflow resistance in the trabecular
meshwork (TM) of the eye [2], although the exact mechanism
and causative factors for this increase is unclear. Up to half of
all patients with POAG have a positive family history [4,5],
and these and other observations suggest that genetic factors
may contribute to POAG [1,6,7].
Myocilin (MYOC) was the first gene linked to POAG
[8] and is the one most studied [9]. It is located in chromosome
1, contains three exons, and codes for a largely extracellular
matrix protein. This protein has an NH2-terminal coiled region
and a COOH-terminal olfactomedin domain [10], but its
function is still not well understood. To date, mutations in
MYOC seem most likely to have their pathogenic effect
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largely because of inability of the protein to fold properly
[11]. This may result in an unfolded protein response in TM
cells, activating a mitochondria-independent apoptosis
pathway which ultimately leads to cell death, breakdown of
TM cell structure, obstruction of aqueous humor outflow
pathway, ocular hypertension, and ultimately the optic nerve
damage of glaucoma [12-14]. MYOC may directly impair
optic nerve function when mutated [15]; however, direct
evidence for this hypothesis is still lacking [11,15].
Most studies investigating MYOC expression in POAG
have employed human cultured TM cells [16,17]. However,
whole blood gene expression studies have been used to
investigate POAG [18], other hereditary optic neuropathies
[19], and diseases affecting brain anatomy and function [20,
21] because the target tissues for these diseases is not readily
available. Therefore, the current study investigated MYOC
expression in whole blood from POAG patients in hope that
this approach will add to our knowledge of whether altered
systemic expression of this gene contributes to POAG
pathogenesis.
METHODS
Patients and controls: Patients (n=47) were evaluated in the
Glaucoma Service at the Wills Eye Institute, Philadelphia, PA,
and enrolled after examination by a glaucoma specialist.
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Patients were eligible for inclusion if they met the following
clinical criteria for POAG [22-25]: age greater than 40 years;
intraocular pressure (IOP) ≥21 mmHg in one or both eyes
before initiation of glaucoma treatment; normal-appearing,
open anterior chamber angles bilaterally by gonioscopy; optic
nerve appearance characteristic of the optic discs typically
observed in primary open-angle glaucoma (with localized
narrowing or absence of the neuro-retinal rim, with the
amount of cupping exceeding the amount of pallor of the rim,
and with asymmetric cupping of the optic discs in the two
eyes); and static visual field (using a full threshold 24–2
program; Humphrey Field Analyzer II; Carl Zeiss Meditec,
Inc., Dublin, CA) showing abnormalities typical of glaucoma
(as per Advanced Glaucoma Intervention Study criteria)
[26]. Good agreement was required between the appearance
of the optic disc and the visual field. Exclusion criteria
included historical, neuroimaging, or biochemical evidence of
another possible optic neuropathic process affecting either
eye, significant visual loss in both eyes not associated with
glaucoma, or choosing not to participate. This research
adhered to the tenets of the Declaration of Helsinki, and all
patients and controls signed an informed consent approved by
the Wills Eye Institute institutional review board.
All control subjects (n=27), frequently spouses of
patients, had full ophthalmologic examinations documenting
IOPs that were <21 mmHg and symmetric in the two eyes,
normal anterior chambers, optic discs that were normal and
symmetric in appearance, entirely normal static perimetry
OU, and no prior history of glaucoma. All controls had static
perimetry performed in the same fashion as POAG patients.
DNA testing: Five ml of peripheral blood were collected in
EDTA tubes from all participating individuals. DNA was
extracted using the Illustra blood genomic Prep Mini Spin Kit
from GE Healthcare (Buckinghamshire, UK), and stored at
−20 °C in aliquots until required.
All patient and control DNA samples were tested for
mutations in MYOC and its promoter. Successfully amplified
fragments were sequenced in both directions using the M13
forward and reverse primers and the BigDye terminator v3.1
cycle sequencing kit (Applied Biosystems, Foster city, CA).
Fragments were then run on the 3130xl Genetic Analyzer
(Applied Biosystems) according to the manufacturer protocol.
All sequenced fragments were then analyzed using SeqScape
software v2.6 (Applied Biosystems). Table 1 details the
sequence of the primers used the PCR annealing temperature
and the expected amplicon size.
Quantitative RT–PCR: A two-step semi-quantitative reverse
transcriptase  polymerase chain reaction (RT–PCR) method
was used to measure gene expression levels of MYOC and β-
globulin (HBB) in POAG patients and controls. Random
hexameres were used as primers in the first step of cDNA
synthesis. Total RNA (1 μg) was combined with 0.5 μg
primers, 200 μM dNTPs, and sterile Milli-Q water (Millipore,
Billerica, MA) and preheated at 65 °C for 2 min to denature
secondary structures. The mixture was then cooled rapidly to
20 °C and then 10 μl 5× RT Buffer, 10 mM dithiothreitol, and
200 U Moloney Murine Leukemia Virus Reverse
Transcriptase (Invitrogen Life Sciences, Grand Island, NY)
were added for a total volume of 50 μl. The RT mix was
incubated at 37 °C for 90 min then stopped by heating at 95 °C
for 5 min. The cDNA stock was stored at −20 °C.
Relative RT–PCR was performed to measure gene
expression of MYOC and HBB according to standard
guidelines [27]. Primer sequences and optimal PCR annealing
temperatures (ta) are listed in Table 2. Primer sequences were
designed to span intron regions to insure that no false positive
PCR fragments would be generated from pseudogenes and
contaminate genomic DNA. In addition, all forward PCR
primers were labeled with fluorescein (6-FAM), making
quantitation more accurate. Polymerase chain reactions were
performed using 100 ng of cDNA, 5 pmoles of each
oligonucleotide primer, 200 μM of each dNTP, 1 unit of
HotStar Taq-polymerase (Qiagen, Valencia, CA) and 1× PCR
buffer in a 20 μl volume. The PCR program initially started
with a 95 °C denaturation for 5 min, followed by 25 cycles of
95 °C for 1 min, ta °C for 45 s, and 72 °C for 1 min. Linear
amplification range for each gene was tested on the adjusted
cDNA, and 25 cycles were found to be optimal for both
TABLE 1. PRIMER SEQUENCES, PCR ANNEALING TEMPERATURE AND AMPLICON SIZE FOR THE MYOCILIN GENE.
Exon Primer sequence Annealing
temp (°C)
Amplicon size
(bp)
Pro-F TGTAAAACGACGGCCAGTGCTGGCTGTTATTTTTCTCTGT 55 592
Pro-R CAGGAAACAGCTATGACCCAGAAGCAGCAGCTGGACA   
1F TGTAAAACGACGGCCAGTCACCCATCCAGGCACCTC 57 775
1R CAGGAAACAGCTATGACCGAGCGCCTGTAGCAGGTCA   
2F TGTAAAACGACGGCCAGTTGGCCGGCAGCCTATTTA 57 325
2R CAGGAAACAGCTATGACCTGGGTGGGCATTTACCCTAT   
3AF TGTAAAACGACGGCCAGTCATCTACTGGCTCTGCCAAG 57 850
3AR CAGGAAACAGCTATGACCAAGTTGTCCCAGGCAAAGAG   
3BF TGTAAAACGACGGCCAGTTGACTACAACCCCCTGGAGA 57 700
3BR CAGGAAACAGCTATGACCCTGCAATCACATCTCCCAAC   
          F=forward; R=reverse; Pro – promoter. Bold and underlined sequences are those of the M13.
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MYOC and HBB. The PCR samples were electrophoresed on
the 3130xl Genetic Analyzer (Applied Biosystems).
Statistical analysis: Absolute RT–PCR values were used to
calculate a ratio of the MYOC peak area in the selected linear
amplification cycle divided by that of HBB, creating an
MYOC/HBB ratio. All clinical and genetic data were analyzed
using SPSS v17 (IBM, Chicago, IL).
RESULTS
Age (POAG patients 67.3 years; controls 63.6 years; p≤0.17)
and sex (POAG 26 males/21 females; controls 12/15; p≤0.18)
of the 47 unrelated POAG patients were similar to the 27
control individuals, but ethnicity differed between the POAG
group (25 Caucasian/22 African American) and the control
group (23 Caucasian/4 African American; p≤0.003).
After aligning and reading all sequences neither POAG
patients nor controls were found to have any significant
mutation or polymorphism in the coding or promoter regions
of MYOC.
Mean gene expression values for both MYOC and HBB
(p≤0.48) were statistically similar in POAG patients and
controls (Table 3). MYOC/HBB ratios (p≤0.90) were also
indistinguishable between POAG patients and controls.
Because of ethnic differences between the POAG group and
controls, gene expression values and ratios were also
compared between Caucasian POAG patients and Caucasian
controls. Mean MYOC (p≤0.90) gene expression and MYOC/
HBB (p≤0.54) ratios also did not differ between these groups.
MYOC/HBB ratios were not significantly associated with
age, sex, or ethnicity of patients within the POAG group
(Table 4). Similarly, MYOC/HBB ratios were not significantly
associated with clinical parameters related to POAG severity,
including maximum intraocular pressure, vertical cup-to-disk
ratio, static perimetry mean deviation, or static perimetry
pattern standard deviation. Power calculations indicate a
power ≤80% on these tests, leaving open the possibility of
false negative type II statistical errors.
DISCUSSION
The 47 patients reported here met rigorous clinical criteria for
POAG [22-25] with elevated IOP, normal anterior chamber,
and evidence on funduscopic exam and visual fields of
glaucomatous optic nerve damage. They did not have
evidence of other types of glaucoma or alternative causes of
optic nerve injury by clinical criteria, and none had
dysmorphism or an obvious genetic syndrome. They were
compared to 27 control individuals in whom POAG and other
evidence of optic nerve damage were carefully excluded.
Screening the full MYOC gene and its promoter region
revealed no mutations or significant polymorphisms in POAG
patients or controls. These results are not surprising, since the
prevalence of MYOC mutations is generally less than 5% in
adult POAG populations [28]. Currently, there are 85
glaucoma causing mutations listed in the comprehensive
myocilin database. They were classified as a glaucoma
causing mutations based on the following criteria: i) predicted
disruption of protein translation (e.g., frame-shift mutations
and premature stop codons); ii) sequence variant frequency in
control (unaffected) populations (those with a frequency >1%
were classified as polymorphisms); iii) variant location (i.e.,
protein homology domain; cross species conservation of
coding sequence); iv) evidence for partial segregation with the
phenotype within a family and v) results of solubility studies.
Interestingly, several sequence changes have been reported in
the MYOC promoter region, but they were defined as neutral
polymorphisms based on the pathologic characteristics
TABLE 2. PRIMER SEQUENCES AND ANNEALING TEMPERATURE β-GLOBULIN AND MYOCILIN FLUORESCENT LABELED PRIMERS.
Primer name Primer sequence Annealing temp (°C)
β-globulin-F (6-FAM)AGCCTCGCCTTTGCCGA 57
β-globulin-R CTGGTGCCTGGGGCG  
MYOC-LAB-F (6-FAM)TTTCTACGTGGAATTTGGACA 59
MYOC-R GTAGGTGGGCTTGGGGTCT  
          F=forward; R=reverse. The forward primers were labeled with 6-FAM.
TABLE 3. MYOCILIN GENE EXPRESSION IN POAG PATIENTS AND CONTROLS.
Parameter Number POAG:control POAG Control p≤
MYOC expression; mean (SD) 47:26 7476 (4325) 6839 (4271) 0.55
β-globulin expression; mean (SD) 44:24 109533 (31355) 103885 (31047) 0.48
MYOC/β-globulin; mean (SD) 42:23 0.0685 (0.0520) 0.0667 (0.0597) 0.90
MYOC expression in Caucasians; mean (SD) 26:22 7132 (4526) 7268 (4121) 0.90
β-globulin expression in Caucasians; mean (SD) 22:20 104941 (31552) 99392 (32171) 0.58
MYOC/β-globulin in Caucasians; mean (SD) 21:19 0.0622 (0.0487) 0.0730 (0.0619) 0.54
          POAG=primary open angle glaucoma; MYOC=myocilin gene expression; SD=standard deviation.
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described above (myocilin). This may indicate that the
promoter region is free of mutations which could alter its
expression. Alternatively, assessing potential pathogenicity
for promoter region sequence changes can be challenging and
may not follow the same pathological criteria as sequence
changes found in coding regions [29].
Expression of MYOC in blood of POAG patients was
unchanged compared to that of controls (Table 3). Expression
was statistically similar to that of the housekeeping gene
HBB, and the normalized expression of MYOC (MYOC/
HBB) also did not differ between patients and controls.
MYOC expression did not differ between Caucasian and
African American POAG patients and ethnicity matched
controls. Finally, MYOC/HBB did not correlate with age or
with various clinical factors associated with POAG such as
visual acuity, IOP, and C/D ratio (Table 4).
The lack of significant change in MYOC expression in
blood of POAG patients stands in contrast to previous studies
documenting decreased expression of MYOC in cultured
human TM cells [16]. Gene expression studies in whole blood
are clearly capable of documenting changes pertinent to
complex neurologic diseases such as autism [30], amytrophic
lateral sclerosis [31], schizophrenia [32],and other psychoses
[33]. Patients with Leber hereditary optic neuropathy, another
spontaneous optic neuropathy with a genetic
pathophysiology, had decreased OPA1 expression in blood
[19]. Similarly, this same POAG patient and control group
exhibited decreased systemic OPA1 expression in blood
[18]. MYOC expression is greatest in the TM [34] and is
dramatically induced by dexamethasone, a glucocorticoid
[17], in human TM cultures, leading to the original name for
the MYOC protein of TM inducible glucocorticoid response
element (TIGR) [35] and supporting the concept that MYOC
may be responsible in part for steroid-induced glaucoma
[36].
A potential limitation of this study is that the number of
individuals studied was relatively small, bringing up the
possibility that the lack of a statistical difference in MYOC
expression and MYOC/HBB ratio between POAG patients and
controls might be due to a type II statistical error because of
inadequate power. This same patient group was adequate to
confirm statistically significant differences in optic atrophy
type 1 (OPA1) expression and the OPA1/HBB ratio between
POAG patients and controls [18], but it is possible that
differences in MYOC expression between POAG patients and
controls are smaller, although still present. Similarly, the lack
of correlation between the MYOC/HBB ratio and various
clinical parameters within the POAG group may be subject to
type II statistical errors. The population studied was
predominantly Caucasian and African-American, and
different results might be obtained in other ethnicities.
We found that systemic MYOC expression was
unchanged in these POAG patients compared to controls. One
interpretation of these results is that the MYOC protein plays
a particularly important role in the globe and that regulation
of MYOC expression that might be pertinent to POAG,
congenital glaucoma, and/or steroid-induced glaucoma is
relatively specific to the TM and may not be reflected to a
significant extent in bone marrow or other non-ocular tissues.
It is also possible that POAG is not altered by wild-
type MYOC expression in any tissue [37]. A gain-of-function
disease model was suggested after identification of mutant,
misfolded forms of the MYOC protein were found aggregated
in the endoplasmic reticulum of TM cells [38]. TM cells are
essential for homeostatic regulation of aqueous humor, and
their disruption may cause elevated intraocular pressure. A
mutation-dependent, gain-of-function association between
human MYOC and the peroxisomal targeting signal type 1
receptor (PTS1R) led to the [39] hypothesis that specific
MYOC mutations may cause different amounts of MYOC
TABLE 4. CORRELATION BETWEEN CLINICAL PARAMETERS AND MYOC/Β-GLOBULIN RATIOS.
Clinical parameter MYOC/β-globulin p≤
Age in years 0.204 0.21
Sex 0.040 0.81
Ethnicity 0.122 0.45
Visual acuity OD 0.016 0.92
Visual acuity OS 0.075 0.64
Maximum IOP OD 0.114 0.48
Maximum IOP OS 0.237 0.14
Vertical c/d ratio OD 0.129 0.43
Vertical c/d ratio OS 0.171 0.29
MD OD −0.042 0.80
MD OS −0.025 0.88
PSD OD 0.211 0.19
PSD OS 0.024 0.89
        MYOC/β-globulin column contains correlation coefficients; OD=right eye; OS=left eye; IOP=intraocular pressure; c/d=cup to
        disk; MD=Humphrey visual field mean deviation; PSD=Humphrey visual field pattern standard deviation.
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misfolding, with corresponding varying degrees of
recognition by the ubiquitin degradation pathway. A greater
opportunity for mutant MYOC to interact with PTS1R may
allow for poorer clearance from the TM endoplasmic
reticulum and greater trabecular cell dysfunction, culminating
in a higher IOP phenotype [39].
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